<DOC>
	<DOCNO>NCT00836368</DOCNO>
	<brief_summary>Purpose : This non-masked study primary endpoint vitro basophil activation allergen D. farinae , compare basophil activation seven day supplementation . Secondary endpoint include circulate antioxidant level ( tocopherols metabolite ) , vitro basophil activation IgG anti-IgE N-formyl-methionyl-leucyl-phenylalanine ( f-met-leu-phe ) , monocyte basophil responsiveness vitro endotoxin challenge . Participants : Twenty allergic asthmatic volunteer Procedures ( method ) : Volunteers give 1200 mg gamma tocopherol enrich supplement , commercially available supplement form vitamin E. Study participant undergo assessment general health , lung function assessment , symptom scoring , epicutaneous skin test allergen baseline supplementation . Blood sample collect baseline 7 day gamma-T treatment .</brief_summary>
	<brief_title>In Vitro Basophil Responsiveness Allergen Challenge After Gamma-tocopherol Supplementation Allergic Asthmatics</brief_title>
	<detailed_description>Oxidant stress play important role mucosal inflammation see asthma . Previous study also show asthmatic individual tend low endogenous level antioxidant vitamin E C , supplement antioxidant decrease exacerbation associate ozone exposure child . We interested future study examine benefit gamma-tocopherol supplementation people allergic asthma . This current study determine gamma tocopherol supplementation reduce allergic response vitro , provide u information allow u design future mask placebo-controlled study potentially important antioxidant vivo allergic response . The purpose study address question vivo gamma-tocopherol supplementation 1200 mg daily blunts allergen-specific inflammatory response vitro . Members group previously show administration 100 mg/kg gamma tocopherol daily four day prior Ova challenge sensitize allergic brown Norway rat prevent eosinophil infiltration airways1 . In addition , dose gamma tocopherol blunt production IL-4 , IL-5 , IL-13 , IFN-gamma nasal airway ; PGE2 , LTB4 cysteinyl leukotrienes pulmonary airway . Mucous cell metaplasia decrease well gamma Tocopherol treatment group 1 . In vivo study gamma tocopherol perform center ( IRB # 05-CEMALB-1407 ) , find daily administration 2 capsule gamma tocopherol rich preparation ( capsule contain 623 mg gamma tocopherol , 61.1 mg d-alpha-tocopherol , 11.1 mg d-beta tocopherol ) , able increase serum level gamma tocopherol 18.6 + 2.6 uM 8 day daily administration ; serum level alpha tocopherol 25.2 + 2.4 uM , delta-tocopherol 5.1 + 1.1 uM2 . Using data vivo study , perform basophil activation test dust mite allergic subject , pretreating blood obtain venipuncture pharmacologic dos attain vivo study gT , aT , gCEHC , aCEHC . We find gT , gCEHC , aCEHC blunt basophil activation induce allergen D. farinae , measure upregulation CD63 cell surface basophil . As secondary aim , also examine effect gamma tocopherol supplementation non-allergic stimulus show activate basophil , IgG anti-IgE N-formyl-methionyl-leucyl-phenylalanine ( f-met-leu-phe ) , well vivo allergen-specific responsiveness epicutaneous skin test supplementation . Exploratory analysis include assess effect gamma tocopherol supplementation monocyte basophil responsiveness vitro endotoxin lipoteichoic acid challenge .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>gamma-Tocopherol</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>1 . Specific allergy House Dust Mite farinae confirm positive immediate skin test response . 2 . Oxygen saturation &gt; 94 % baseline 3 . Blood pressure within follow parameter ( Systolic 140 90 , Diastolic 9060 mm Hg ) 4 . Moderate severe persistent asthma accord NHLBI definition include history one following : 1 . Episodic wheezing , chest tightness shortness breath consistent asthma occur least week may affect activity 2 . Asthma symptoms occur night sleep least 1 time per week 3. measure FEV1 FVC &lt; 80 % predict OR 4 . Physician diagnose moderate severe persistent asthma currently treat control maintenance medication include moderate high dose inhale corticosteroid , dose inhaled corticosteroid longacting inhaled B2agonist 1 . Any chronic medical condition consider PI contraindication receive gammaT , include significant cardiovascular disease , diabetes require medication , chronic renal disease , chronic thyroid disease , kidney disease coagulation defect . 2 . Use inhaled steroid , cromolyn leukotriene inhibitor ( Montelukast Zafirlukast ) use least one month allow . Patients must stable regimen maintenance asthma therapy change past month prior entrance study . 3 . Nonsteroidal AntiInflammatory Drugs ( NSAIDS ) aspirin ( ASA ) use within 48 hour begin study , inability suspend use medication length study . 4 . Use anticoagulant include warfarin , heparin , clopidogrel . 5 . Diagnosis anemia abnormal blood count screen . Abnormal PT PTT value screen ( PT prolong 12 sec PTT prolong 35 sec normal . The normal value use define McLendon lab . ) 6 . Pregnancy nurse baby . As phase I study , potential risk fetus justify . 7 . Children include study potential risk grow child justified . 8 . Adults age 51 older exclude potential concomitant illness population increase risk confound data . 9 . Known vagal response venipuncture 10 . Use tobacco product within past 6 month 11 . Hypertension , classify systolic blood pressure equal great 140 , diastolic blood pressure equal great 90 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Asthmatic</keyword>
	<keyword>Allergy</keyword>
	<keyword>Allergic</keyword>
	<keyword>Gamma-tocopherol</keyword>
	<keyword>Vitamin</keyword>
	<keyword>Vitamin E</keyword>
</DOC>